In those reports, treatment of CD4+ T cells from RA patients with the pro-oxidant, plumbagin, reduced the frequencies of Th1 and Th17 cells, as well as decreasing production of the inflammatory cytokines, TNF-α and IL-6. The gene discussed is CD4; the disease is rheumatoid arthritis.